Effects of Cancer Chemotherapy on the Blood Fibrinogen Concentrations of Cancer Patients
|
|
- Ann Leonard
- 6 years ago
- Views:
Transcription
1 The Journal of International Medical Research Endovascular 2000; 28: Embolization of Effects of Cancer Chemotherapy on the Blood Fibrinogen Concentrations of Cancer Patients D-Y LU 1, X-L CHEN 2, J-Y CAO 1, Z LI 2, H-W XUE 2, L-J LUO 2 AND B XU 3 1 School of Life Sciences, Shanghai University, Shanghai, People s Republic of China; 2 Central Hospital of Jing-An District, Shanghai , People s Republic of China; 3 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People s Republic of China Blood fibrinogen concentrations and glutamic pyruvic transaminase activities of 66 adult cancer in (aged years) were determined both before and after one or two chemotherapy regimens. The percentage of hepatoma with abnormal blood fibrinogen levels (< 1.5 or > 6.0 g/l) was higher (64.3% of 14 ) than that in other cancer categories (19.2% of 52 ). The mean blood fibrinogen concentrations of male (3.5 g/l) and female (4.5 g/l) cancer were higher than those previously reported for healthy humans (2.8 and 2.9 g/l, respectively). After chemotherapy, blood fibrinogen concentrations decreased in whose primary tumours were surgically removed (from 4.8 to 3.2 g/l) but increased (from 3.0 to 4.8 g/l) in those who did not undergo surgery. Glutamic pyruvic transaminase activities did not appear to be related to blood fibrinogen levels. We conclude that the increase in mean blood fibrinogen levels of cancer is probably related to tumour growth. Different mechanisms may operate in with hepatoma. KEY WORDS: FIBRINOGEN; BLOOD FIBRINOGEN CONCENTRATION; CANCER CHEMOTHERAPY; TUMOUR PATHOGENESIS 313
2 D-Y Lu, X-L Chen, J-Y Cao INTRODUCTION The relationship between fibrinogen or fibrin concentrations within the body and solid tumours is of continuing interest to experimental biologists and clinical oncologists. 1 Experimental data suggest that there are three possible ways in which fibrinogen or fibrin may be involved in tumour growth and metastasis: (i) it may form a scaffold to which tumour cells can attach as tumour stroma; (ii) it may form a tumour cocoon to shield tumour cells from attack by activated lymphocytes; (iii) it may help angiogenesis in tumour tissues. 2,3 Blood fibrinogen, a precursor of fibrinogen and fibrin in tumours, was found to be increased in mice bearing solid tumours, 4 and some antitumour drugs, such as L-4-oxalysine, 5 have been found, in experimental models, to inhibit the blood fibrinogen levels of mice bearing solid tumours. Whether there are differences in blood fibrinogen concentrations between healthy individuals and cancer in clinics has not been assessed clinically. It has, however, been suggested that some antineoplastic drugs, other than anticoagulants, may affect tumour metastasis via the fibrinogen pathway. 6,7 An understanding of the relative fibrinogen levels of healthy individuals and cancer might also be useful in the development of prognostic forecasting and might assist the selection of appropriate chemotherapy regimens. We therefore collected clinical data on fibrin levels in cancer and compared them with those of healthy individuals. PATIENTS AND METHODS In (aged years), diagnosed (by pathological or B-ultrasonic wave evaluation) as having late-stage cancers of various origins were enrolled. Blood fibrinogen contents and glutamic pyruvic transaminase (GPT) activities were determined by routine methods both before treatment and after one or two conventional chemotherapy regimens (drugs including camptothecin, cisplatin, carboxyplatin, adriamycin, bleomycin, arabinosyl cytosine or VP16, etc, in single or combined protocols). Blood (3 ml) was anticoagulated with sodium citrate. After centrifugation at 2000 g for 10 min, 0.5 ml of plasma was taken and fibrinogen was precipitated by calcium salt. The fibrinogen was dissolved in sodium hydroxide solution and was assayed using the method of Lowry 8 The data were compared using Student s t-test. We also collected the corresponding data from who had been admitted to the hospital with non-cancer conditions. RESULTS Fifty male and 50 female in (aged years) with non-cancer conditions were included in the statistical analysis. In the cancer-patient group, totals of 34 male and 32 female were included. They had a diverse range of cancers, including cancer of the lung, stomach, liver, colon, mammary cancer, etc. Treatment regimes were likewise diverse and varied according to the origin of cancer. The initial mean blood fibrinogen concentrations of these were 3.48 g/l and 4.47 g/l, respectively. Of the 14 with hepatoma, nine (64.3%) had abnormal blood fibrinogen concentrations (< 1.5 g/l or > 6 g/l): in six the concentrations were < 1.5 g/l and in three they were > 6 g/l. Among the other 52, the proportion of with abnormal fibrinogen concentrations was 19.2%, similar to that found among otherwise healthy humans (20%). Patients who had tolerated a complete chemotherapy regimen (n = 33) showed a slight decrease in blood fibrinogen levels after chemotherapy, 314
3 D-Y Lu, X-L Chen, J-Y Cao from 3.99 to 3.58 g/l (P = 0.213). Fifteen who had not undergone operations showed an increase of blood fibrinogen concentrations from 2.99 to 4.82 g/l (P = 0.026). Eighteen whose tumours had been removed by operations showed a decrease in blood fibrinogen levels (from 4.82 to 3.15 g/l; P = 0.048). No discernible correlation between blood fibrinogen levels and GPT activity was found. DISCUSSION In the present study the mean blood fibrinogen levels in cancer were 3.48 and 4.47 g/l in males and females, respectively, compared with 2.76 and 2.90 g/l, respectively, in healthy adults. 9 This escalation of blood fibrinogen levels may result from enhancement of the synthesis of fibrinogen or from inhibition of its decomposition. The first mechanism is likely to result from genetic changes in the themselves, so we considered the genetic status of fibrinogen biosynthesis in the. According to Southan, 9 abnormal blood fibrinogen concentrations, both low (< 1.5 g/l) and high (> 6 g/l) concentrations, 10 are linked to genetic fibrinogen synthesis status, 8 and his data indicate that the frequency of abnormal fibrinogen concentrations among healthy people is 20%. In the present study, we found that abnormal blood fibrinogen concentrations occurred in 19.2% of cancer, apart from those with hepatoma, a frequency very similar to that found in healthy individuals. We deduced that the increased mean blood fibrinogen levels seen in cancer do not result from increases in the production of fibrinogen in, but are more likely to be attributable to tumour growth. This deduction was further supported by the finding that the blood fibrinogen concentrations of whose tumours were removed by operation was reduced, while the blood fibrinogen concentrations of who did not undergo surgery was increased. It appears that the escalation of fibrinogen is related to the presence of the tumour rather than being a characteristic of the themselves. It is thus possible that tumours produce factors that hinder the speed of degradation or cross-linking of fibrinogen in blood and that also affect the transformation of fibrinogen into fibrin in tumours (the activity of antithrombin, etc). 6 This is why many (two-thirds of all cancer ) have higher than normal blood fibrinogen levels but have common fibrinogen levels in tumour tissues. 3,11,12 Since the liver is the primary source of fibrinogen synthesis in the body (liver mesenchyme produces fibrinogen), it is not surprising that with hepatoma are more likely to show enhanced blood fibrinogen levels than with other tumour types. The present results indicate that the blood fibrinogen levels of are hardly influenced by chemotherapy if the tumour is not surgically removed. Some chemotherapy drugs, other than anticoagulants, reduced both blood fibrinogen levels and cancer metastasis in whose tumours were removed. We have previously found that antitumour drugs can affect the relationship between tumour and fibrinogen in vitro. 6,7 There are two possible explanations: (i) that the inhibition of tumour growth reduces the blood fibrinogen levels; (ii) that the drugs reduce the blood fibrinogen levels directly as in vitro. Fibrinogen itself can inhibit cytotoxic lymphocytes from attacking tumour cells, 2,3,13,14 and lower fibrinogen concentrations in the body can increase the defensive effects of the immune system and inhibit tumour growth. This mechanism 315
4 D-Y Lu, X-L Chen, J-Y Cao is considered to be among those by which many antitumour drugs can promote the survival of cancer. 6,7 ACKNOWLEDGEMENT This work was supported by grants from the Science and Technology Foundation of Shanghai High Education (No. 97A49). REFERENCES 1 Zacharski LR: Anticoagulation in the treatment of cancer in man. In: Malignancy and Hemostatic System (Donati MB, Davidson J, Garattini S, eds). New York: Raven Press, 1981; pp Dvorak HF, Senger DR, Dvorak AM: Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2: Costantini V, Zacharski LR: The role of fibrin in tumor metastasis. Cancer Metastasis Rev 1992; 11: Poggi A, Polentarutti N, Donati MB, et al: Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. Cancer Res 1977; 37: Yue XF, Wu FG, Xu B: Effect of oxalysine on plasma fibrinogen content in tumorbearing mice. Acta Pharmacologica Sinica 1982; 3: Lu DY, Cao JY, Huang YP, et al: Comparison of some antineoplastic drugs on inhibiting thrombin catalizing fibrinogen clotting in vitro. Chin Med J (Engl) 1999: 112: Lu DY, Zhou PQ, Xu B: Homoharringtonine and razoxane reduce the binding of 125 I-fibrinogen to leukemia P388 and HL60 cells. Acta Pharmacologica Sinica 1995; 16: Lowry OH, Rosebrough NJ, Farr AL, et al: Protein measurement with the Folinphenol reagent. J Biol Chem 1953; 193: Southan C: Molecular and genetic abnormalities of fibrinogen. In: Fibrin, Fibrin Stabilisation and Fibrinolysis (Francis JL, ed). Chichester: Ellis Horwood Ltd, 1988; pp Fried K, Kaufman S: Congenital afibrinogenaemia in 10 offspring of uncle niece marriage. Clin Genet 1980; 17: Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al: Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991; 67: Zacharski LR, Henderson WG, Rickles FR, et al: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of the VA cooperative study 75. Cancer 1984; 53: Gunji Y, Gorelik E: Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cell. Cancer Res 1988: 48: Cardinali M, Uchino R, Chung SI: Interaction of fibrinogen with murine melanoma cells: covalent association 316
5 D-Y Lu, X-L Chen, J-Y Cao with cell membrane and protection against recognition by lymphokineactivated killer cells. Cancer Res 1990; 50: D-Y Lu, X-L Chen, J-Y Cao, Z Li, H-W Xue, L-J Luo and B Xu Effects of Cancer Chemotherapy on the Blood Fibrinogen Concentrations of Cancer Patients The Journal of International Medical Research 2000; 28: Received for publication 17 April 2000 Accepted 25 April 2000 Copyright 2000 Cambridge Medical Publications Address for correspondence DR D-Y Lu School of Life Sciences, Shanghai University, Shanghai , People s Republic of China. 317
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask
More informationLocal vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors
Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help
More informationEvaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues
Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Kristi J. Smock, MD Associate Professor of Pathology University of Utah Health Sciences Center Medical Director, Hemostasis/Thrombosis
More informationCoagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.
Coagulation Cascade Intrinsic Pathway Extrinsic Pathway Contact Activation XIIa XI XIa Prekallikrein HMW Kininogen IX IXa Ca 2+ Anticoagulation proteins: Protein C, Protein S, Antithrombin III, TFPI TF
More informationSEED Coagulation. Sysmex Educational Enhancement and Development April 2014
SEED Coagulation Sysmex Educational Enhancement and Development April 2014 The Thrombin Time Test and Reptilase Test what is their role in coagulation testing? Baseline screening tests of coagulation The
More informationChanges in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase
Clinical Hemorheology and Microcirculation 23 (2000) 213 218 213 IOS Press Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase Lirong Jin
More informationPlasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.
Test Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Karen A. Moffat BEd, MSc, ART, FCSMLS(D) Technical Specialist, Coagulation, HRLMP Assistant Professor, Department of
More informationThe Cardiovascular System: Blood
The Cardiovascular System: Blood The Functions of Blood General Overview Provides a system for rapid transport within the body Nutrients Hormones Waste products Respiratory gases Cells & Blood Components
More informationSysmex Educational Enhancement and Development No
SEED Haematology Sysmex Educational Enhancement and Development No 3 2014 The Thrombin Time test and Reptilase test what is their role in coagulation testing? The purpose of this newsletter is to provide
More informationCoagulation Mechanisms Dr. Nervana Bayoumy
Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand
More informationSession 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
More informationLinking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity
Linking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity Abhishek Gulati What is enoxaparin? Low molecular weight heparin anticoagulant Used to minimise the
More informationActivated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?
Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia
More informationPrincess Alexandra Hospital Emergency Department. Clinical Procedure. 1 Introduction
Princess Alexandra Hospital Emergency Department Clinical Procedure Trauma, Resuscitation Review Officer: Glenn Ryan 1 Introduction Version no: 1 Approval Date: 16/07/2014 Review Date: 16/07/2016 Authority:
More informationCh 13: Blood. What does blood do? Transport: Regulation: Protection:
Ch 13: Blood What does blood do? Transport: Regulation: Protection: SLOs Describe the composition of plasma and list the major functions of plasma proteins. Map hematopoiesis, starting from a pluripotent
More informationFibrinogen Universal Kit
Order references Reagents CONT FITUR-B00 Universal kit 1 x 50 ml R1 + 1 x 5 ml R2 FITUR-00 Universal kit 2 x 50 ml R1 + 1 x 15 ml R2 FITUR-C00 Universal kit 2 x 17 ml R1 + 1 x 4 ml R2 Other necessary products
More informationClinical Procedure. ROTEM Trauma, Resuscitation. Princess Alexandra Hospital Emergency Department. 1 Introduction
Princess Alexandra Hospital Emergency Department Clinical Procedure Trauma, Resuscitation Review Officer: Glenn Ryan 1 Introduction Version no: 1 Approval Date: 16/07/2014 Review Date: 16/07/2016 Authority:
More informationPhysiology Unit 3 HEMATOLOGY
Physiology Unit 3 HEMATOLOGY In Physiology Today Hematocrit Percentage of blood volume that is erythrocytes 45% in men 42% in women Average blood volume in is 5 L Plasma Large amounts of organic/inorganic
More informationA Rapid, Quantitative Determination of Clottable Fibrinogen Unaffected by Heparin
A Rapid, Quantitative Determination of Clottable Fibrinogen Unaffected by Heparin EDWARD J. HERSHGOLD, M.D., AND BARBARA MARTIN, BA (CSLT) Departments of Medicine and Pathology, University of Utah College
More informationStability of Plasma for Add-On PT and APTT Tests
COAGULATION AND TRANSFUSION MEDICINE Original Article Stability of Plasma for Add-On PT and APTT Tests DEMETRA NEOFOTISTOS, MT, MARIA OROPEZA, MT(ASCP), AND CHUNG-HSIN TS'AO, PhD We conducted studies to
More informationLABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency
More informationType of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis.
Coagulation disorders induced by L-asparaginase: correction with and without fresh-frozen plasma Glasmacher A, Kleinschmidt R, Unkrig C, Mezger J, Scharf R E Record Status This is a critical abstract of
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Pharmacy Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients
More informationEDUCATIONAL COMMENTARY STRAIGHT TALK ABOUT THE D-DIMER
EDUCATIONAL COMMENTARY STRAIGHT TALK ABOUT THE D-DIMER Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits
More informationIn vitro Human Umbilical Vein Endothelial Cells (HUVEC) Tube-formation Assay. Josephine MY Ko and Maria Li Lung *
In vitro Human Umbilical Vein Endothelial Cells (HUVEC) Tube-formation Assay Josephine MY Ko and Maria Li Lung * Clinical Oncology Department, The Univerisity of Hong Kong, Hong Kong, Hong Kong SAR *For
More informationGeneral Principles of. Hemostasis. Kristine Krafts, M.D.
General Principles of Hemostasis Kristine Krafts, M.D. Hemostasis is a balancing act! pro-ting plugs up holes in blood vessels anti-ting keeps ting under control Pro-Clotting Pro-Clotting vessels platelets
More informationThe Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli
The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management Elham Khalaf Adeli Overview PBM, bleeding management, Coagulation POC Testing Review of laboratory conventional coagulation
More informationSection 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS)
Section 8 Practicalities Blood Collection Aim To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS) Learning Outcomes To identify the equipment used for
More informationEDUCATIONAL COMMENTARY D-DIMER UPDATE
EDUCATIONAL COMMENTARY D-DIMER UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing
More informationDEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 COAGULATION COMPETENCY EVALUATION FORM STUDENT NAME:
More informationVenous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? New Chest Guidelines 2016
Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? Marlene Grenon, MD Associate Professor of Surgery University of California San Francisco UCSF Vascular Surgery Symposium
More informationSurgical Adhesives in Facial Plastic Surgery
Surgical Adhesives in Facial Plastic Surgery Dean M. Toriumi, Victor K. Chung, Quintin M. Cappelle University of Illinois at Chicago Chicago, IL Supplement to Toriumi DM, Chung VK, Cappelle QM. Surgical
More informationPV92 PCR Bio Informatics
Purpose of PCR Chromosome 16 PV92 PV92 PCR Bio Informatics Alu insert, PV92 locus, chromosome 16 Introduce the polymerase chain reaction (PCR) technique Apply PCR to population genetics Directly measure
More informationCoagulopathy Case-2. Andy Nguyen, M.D. 2009
Coagulopathy Case-2 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 42 year-old man brought to the emergency room with severe burn. Patient was rescued by firemen in a serious fire. He had been found unconscious
More informationFibrinogen Universal Kit
Order references Reagents CONT FITUR-B00 Universal kit 1 x 50 ml R1 + 1 x 5 ml R2 FITUR-00 Universal kit 2 x 50 ml R1 + 1 x 15 ml R2 FITUR-C00 Universal kit 2 x 17 ml R1 + 1 x 4 ml R2 Other necessary products
More informationWhat is an Aptamer? smallest unit of repeating structure
What is an Aptamer? apto: mer: to fit smallest unit of repeating structure Aptamers are single stranded folded oligonucleotides that bind to molecular (protein) targets with high affinity and specificity
More informationMarcia L. Zucker, Ph.D. ZIVD LLC
Marcia L. Zucker, Ph.D. ZIVD LLC 1 Monitoring hemostasis Bleeding Clotting 2 Picture courtesy of Helena Laboratories 3 Extrinsic Pathway Monitor with ACT / aptt WARFARIN Monitor with PT Common Pathway
More informationPROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY)
PROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY) PROTHROMBIN TIME DEFINITION The Prothrombin time is the functional determination of the extrinsic coagulation pathway. It is a widely used laboratory
More informationWORTHAM LABORATORIES, INC. DRAFT Thrombin Reagent
WORTHAM LABORATORIES, INC. DRAFT Thrombin Reagent Intended Use Wortham Laboratories Thrombin Reagent is intended for thrombin to convert fibrinogen in the quantitative determination of fibrinogen in plasma
More informationLaboratory Testing Issues for Protein C, Protein S and Antithrombin Assays
Laboratory Testing Issues for Protein C, Protein S and Antithrombin Assays Richard A. Marlar Ph.D. University of Oklahoma THSNA Meeting- Chicago, IL April 14-16, 2016 DISCLOSURE Richard A. Marlar, PhD
More informationTSOAC Case Study 1. Question. TSOAC Case Study 1 Continued
TSOAC Case Study 1 An otherwise healthy 56-year-old man presents to the emergency department with left leg pain and swelling for the last 3 days. Compression ultrasonography confirms left common femoral
More informationAdenine % Guanine % Thymine % Cytosine %
1. Explain each of the following statements in terms of your knowledge of the structure and function of DNA. (i) In all living organisms the ratio species to another. A C T G is constant but the ratio
More informationBYA3. General Certificate of Education June 2006 Advanced Subsidiary Examination. HUMAN BIOLOGY (SPECIFICATION A) Unit 3 Pathogens and Disease
Surname Other Names Leave blank Centre Number Candidate Number Candidate Signature General Certificate of Education June 2006 Advanced Subsidiary Examination HUMAN BIOLOGY (SPECIFICATION A) Unit 3 Pathogens
More informationStem Cells and Multiple Myeloma
Stem Cells and Multiple Myeloma What is Multiple Myeloma Multiple Myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow Plasma cells normally make proteins called
More informationCoagulation in perspective: Blood management. Objectives
Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationIn Vitro Angiogenesis Assay Kit
In Vitro Angiogenesis Assay Kit Catalog Number KA1323 100 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay...
More informationDisclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1
Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1 Learning Objectives Explain the concept of thrombophilia Recognize
More informationORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon
ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT Dr Philippe CASSIER Centre Léon Bérard, Lyon Outline Cancer & Oncology Drug development in oncology Specificity of phase I trials in oncology Study design
More informationPrimary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system
Primary hemostasis Vascular endothelium Vasoconstriction : local tissue factor, nervous system Platelet Plug Platelet Adhesion Platelet Activation Platelet Aggregation Platelet Plug Formation Secondary
More informationEmergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s
Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency Hemostasis Testing Patients actively bleeding
More informationManejo de la transfusión de plaquetas. Ileana López-Plaza, MD
Manejo de la transfusión de plaquetas Ileana López-Plaza, MD Thrombocytopenia Common in ICU setting 25-38% with< 100,000/µL 2-3 % with < 10,000/µL Common etiologies Drug-induced: heparin, antibiotics,
More informationAdv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file:
Adv Pathophysiology Unit 4 Page 1 of 10 Learning Objectives for this file: Topics include structure & function of: 1. Coagulation process platelets, clotting factors 2. Coagulation cascade formation of
More informationDisclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications
Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label
More informationSign up to receive ATOTW weekly
RECOMBINANT HUMAN ACTIVATED PROTEIN C IN THE TREATMENT OF SEVERE SEPSIS ANAESTHESIA TUTORIAL OF THE WEEK 133 11 TH MAY 2009 Dr Richard Eve, Royal Cornwall Hospital, Cornwall, UK Correspondence to richardlloydeve@gmail.com
More informationHematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม
Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม Hematotoxin producing snakes Pit vipers (Crotalinae) Malayan pit viper (Calloselasma rhodostoma) Green pit viper (Trimeresurus
More informationNote: The taller 100 x 13 mm tube is not designed to run on the ACL TOP. Plasma after centrifugation of these tubes must be placed in sample cups.
Created Revised Reviewed Approved Lupus Insensitive aptt on the ACL TOP HEM 4.15.1 7/13/2012 4/11/2013 4/11/2013 4/11/2013 I. PRINCIPLE The activated partial thromboplastin time is a global screening procedure
More informationTITLE: Molecular Targeting of the P13K/Akt Pathway to Prevent the Development Hormone Resistant Prostate Cancer
AD Award Number: TITLE: Molecular Targeting of the P13K/Akt Pathway to Prevent the Development Hormone Resistant Prostate Cancer PRINCIPAL INVESTIGATOR: Jonathan Walker, M.D. CONTRACTING ORGANIZATION:
More informationDisclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018
Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested
More informationLina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof
2 Lina Al-Lawama Rama Al-Ashqar Malik Al-Zohlof Anticoagulant drugs Recap Last lecture we were talking about antiplatelet drugs, we mentioned 5 drugs : Aspirin which is used alone with patents that have
More informationK,C,O4 solution to seven parts of fresh blood and centrifuging
ON THE INACTIVATION OF THROMBIN BY PLASMA PROTEIN By JOHN D. STEWART mm G. MARGARET ROURKE (From the Surgical Laboratories of the Harvard Medical School at the Massachusetts General Hospital, Boston) It
More informationUvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication
UvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication Citation for published version (APA): van Montfoort, M. L. (2014). Factor XI
More informationWhat Can We Learn from Animal Models of Coagulopathy and Bleeding (about plasma transfusion)?
Test What Can We Learn from Animal Models of Coagulopathy and Bleeding (about plasma transfusion)? William Sheffield Associate Director, Research CBS Centre for Innovation, and Professor, Pathology and
More informationStem Cell Research From Bench to Bedside
Stem Cell Research From Bench to Bedside Stem Cell Dialogues Jan A. Nolta, Ph.D. Professor, Internal Medicine Director, UC Davis Institute for Regenerative Cures October 26, 2010 Stem Cells at UC Davis
More informationUse of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey
VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research
More informationDeep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources
Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep Mark Crowther on behalf many Some slides modified from other sources 1 Disclosures Major disclosure: Paid consulting with Portola,
More informationANEMIA. Oral iron. IV iron gluconate (order set #233)
PREVENTION ANEMIA Oral iron IV iron gluconate (order set #233) TRANSEXAMIC ACID Efficacy of IV TXA in Reducing Blood Loss After Elective C-section: Prospective, Randomized, Double-blind, Placebo Controlled
More informationCoaDATA product list valid from
Milan Analytica AG Baslerstrasse 15 4310 Rheinfelden www.milananalytica.ch ** = Smaller Kit Format specifically designed for Helena C-1/2/4/AC-4 ^ = For use with Helena C-1/2/4/AC-4 CoaDATA product list
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationEstablishment and verification of mirnas expression molecules for breast cancer and its distant metastasis Yanhong Gao Associate Professor
Establishment and verification of mirnas expression molecules for breast cancer and its distant metastasis Yanhong Gao Associate Professor Department of Clinical Biochemistry Chinese PLA General Hospital
More informationManagement of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015
+ Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Disclosures Off label use of PCC and apcc will be discussed My centre participates
More informationHypercoagulation. CP Conference 11/14/2006
Hypercoagulation CP Conference 11/14/2006 Overview Hypercoagulation: poorly understood phenomena No definite cause is identified in > 40% of cases Three major factors in thrombus formation (Rudolf Virchow,
More informationROZAIMAH ZAIN-HAMID. Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara
ROZAIMAH ZAIN-HAMID Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara Drugs Used in Disorders of Coagulation Fibrinolytic drugs Anti-thrombotic thrombotic drugs
More informationMedical Staff, House Staff, Patient Care Centers, Outpatient Clinics and UC Med Labs Clients
TO: FROM: Medical Staff, House Staff, Patient Care Centers, Outpatient Clinics and UC Med Labs Clients Krzysztof Mikrut, B.S. MT (ASCP) Technical Director, Coagulation Laboratory Jonathan L. Miller, M.D.,
More informationROTEM Basic Interpretation Guide
ROTEM Basic Interpretation Guide Parameter: Clotting Time CT - Clotting Time (seconds) The time from the start of the test until first significant levels of a clot are detected. This measurement is initiated
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 29 July 2004 CPMP/BPWG/1089/00 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL INVESTIGATION OF PLASMA
More informationThymosin (Alpha-1) EIA
Thymosin (Alpha-1) EIA For the quantitative determination of Thymosin alpha 1 in serum and thymus extracts. For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 30-9510 Size: 96
More informationLaboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016
Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016 Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be
More informationTumor Growth Suppression Through the Activation of p21, a Cyclin-Dependent Kinase Inhibitor
Tumor Growth Suppression Through the Activation of p21, a Cyclin-Dependent Kinase Inhibitor Nicholas Love 11/28/01 A. What is p21? Introduction - p21 is a gene found on chromosome 6 at 6p21.2 - this gene
More informationUse of Chromogenic Assay of Factor X to Accept or Reject INR Results in Warfarin Treated Patients
CM&R Rapid Release. Published online ahead of print July 22, 2009 as Use of Chromogenic Assay of Factor X to Accept or Reject INR Results in Warfarin Treated Patients Michael J. Sanfelippo, MS, MT ASCP;
More information7th Annual Shanghai Symposium on Clinical and Pharmaceutical Solutions through Analysis
Mechanistic Physiological PhysioPD Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach Sharan A Pagano SVP, Scientific Alliances at Rosa & Co. LLC 7th Annual Shanghai
More informationCharacteristics. Capable of dividing and renewing themselves for long periods of time (proliferation and renewal)
STEM CELLS (p 2-8) Overview The body is made up of about 200 different kinds of specialised cells, such as muscle cells, nerve cells, fat cells and skin cells. Cells with the capacity to give rise to the
More informationASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS
ASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS Jean AMIRAL, President HYPHEN BioMed (France) Fibrinolysis Functions Neurology (brain) Fertility Cell Remodelling FIBRINOLYSIS Malignancy (metastasis)
More informationImproving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm
Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Summer Syed (local PI) Keyvan Karkouti Deputy Anesthesiologist-in-Chief, Toronto General Hospital, University Health
More informationDrugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014
Drugs used in Thromboembolic Disease Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Anticoagulants: Heparin. Oral anticoagulants.
More informationUnderstanding brain diseases from stem cells to clinical trials
Understanding brain diseases from stem cells to clinical trials Alan Mackay Sim Griffith Institute for Drug Discovery Griffith University Brisbane, QLD Making ES cells Fertilise an egg Put in a dish Embryonic
More informationNew test for transplant rejection on the horizon
December 6, 2004 New test for transplant rejection on the horizon Vancouver Researchers at St. Paul s Hospital and Vancouver General Hospital are developing a revolutionary new test to diagnose and facilitate
More informationProduct Datasheet and Instructions for Use
Product Datasheet and Instructions for Use Product Code: MP-323-CM01 (0.1ml conc) MP-323-CM05 (0.5ml conc) Product Description: CD24 Concentrated Monoclonal Antibody Control Number: 901-323-052510 ISO
More informationData Sheet. TDO Cell-Based Assay Kit Catalog #72033
Data Sheet TDO Cell-Based Assay Kit Catalog #72033 6044 Cornerstone Court W, Ste E Background L-tryptophan (L-Trp) is an essential amino acid necessary for protein synthesis in mammalian cells and the
More informationPharmacology Lecture 5. Anticoagulants
Pharmacology Lecture 5 Anticoagulants General overview Anti-thrombotic Drugs Antiplatlets Anticoagulants Fibrinolytics Anticoagulants Indirect Thrombin Inhibitors Anti-thrombotic effect is exerted by interaction
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More informationUse of ROTEM from the Laboratory Perspective. A/Prof David Roxby SA Pathology
Use of ROTEM from the Laboratory Perspective A/Prof David Roxby SA Pathology What s the Problem? Constant changes in treatment recommendations Lack of good evidence to guide practice Variations in clinical
More informationInterventional Tumor Therapy Minimally Invasive, Maximally Effective
Cover Story Interventional Oncology Interventional Tumor Therapy Minimally Invasive, Maximally Effective There is a continuous expansion of indications for interventional therapies in oncology. Thanks
More informationThe Tri-F Titer. Fibrinolysis, Fibrin(ogen) Split Products, and Heparin. Cary J. Lambert, M.D., Alain J. Marengo-Rowe, M.D.,
A Rapid Test for Estimation of Plasma Fibrinogen and Detection of Fibrinolysis, Fibrin(ogen) Split Products, and Heparin Cary J. Lambert, M.D., Alain J. Marengo-Rowe, M.D., James Leveson, Ph.D., Peter
More informationGuideline on core SmPC for human fibrinogen products
23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation
More informationA STUDY OF CANCER IMMUNITY BY THE METHOD OF CULTIVATING TISSUES OUTSIDE THE BODY.*
A STUDY OF CANCER IMMUNITY BY THE METHOD OF CULTIVATING TISSUES OUTSIDE THE BODY.* BY ROBERT A. LAMBERT, M.D., Am) FREDERIC M. HANES, M.D. (From the Department of Pathology of the College of Physicians
More informationMarilyn Johnston Hemostasis Reference Laboratory Hamilton,Ontario
Marilyn Johnston Hemostasis Reference Laboratory Hamilton,Ontario None Discovered in 1916 Named from the Latin word for liver, hepar 1939, heparin requires a plasma cofactor First used in humans in 1940
More informationDifferential effects of the direct thrombin inhibitor dabigatran etexilate vs warfarin on platelet function
Differential effects of the direct thrombin inhibitor dabigatran etexilate vs warfarin on platelet function Giulia Renda 1, Gelsomina Malatesta 1, Valentina Bucciarelli 1, Alessia Napoleone 1, Loredana
More informationUsing TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS
Using TEG in the ED, OR, and ICU Don H. Van Boerum, MD, FACS Trauma Surgeon, Director of Surgical Critical Care, Co-Director of Shock Trauma ICU, Intermountain Medical Center, Intermountain Healthcare
More informationSpecial Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:
Special Coagulation - APC Resistance DiaPharma Group, Inc. Customer Service: 1.800.526.5224 Technical Support:1.800.447.3846 www.diapharma.com 1 Review of Hemostasis Overview Pathways of coagulation, anticoagulation,
More information